The Usefulness of Wireless Ambulatory pH Monitoring for Prediction of Response to Proton Pump Inhibitor Treatment in Patients with Globus Sense

In Du Jeong

doi:10.4166/kjg.2015.65.2.73

Journal List > Korean J Gastroenterol > v.65(2) > 1007399

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jeong: The Usefulness of Wireless Ambulatory pH Monitoring for Prediction of Response to Proton Pump Inhibitor Treatment in Patients with Globus Sense

Editorial

Korean J Gastroenterol 2015;65(2):73-75.

Published online: 4 October 2015

DOI: https://doi.org/10.4166/kjg.2015.65.2.73

The Usefulness of Wireless Ambulatory pH Monitoring for Prediction of Response to Proton Pump Inhibitor Treatment in Patients with Globus Sense

In Du Jeong

Department of Gastroenterology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea

Correspondence to: In Du Jeong, Department of Gastroenterology, Ulsan University Hospital, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan 682-714, Korea. Tel: +82- 52-250-7029, Fax: +82-52-250-7048, E-mail: jidmd@uuh.ulsan.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Prediction of the Response to Proton Pump Inhibitor Treatment Using Wireless Ambulatory pH Monitoring in Patients with Globus Sense

References

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101:1900–1920.

2. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001; 96:979–983.

3. Sontag SJ, O'Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol. 2003; 98:987–999.

4. Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope. 2001; 111:2147–2151.

5. Eherer AJ, Habermann W, Hammer HF, Kiesler K, Friedrich G, Krejs GJ. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. Scand J Gastroenterol. 2003; 38:462–467.

6. Garrigues V, Gisbert L, Bastida G, et al. Manifestations of gastroesophageal reflux and response to omeprazole therapy in patients with chronic posterior laryngitis: an evaluation based on clinical practice. Dig Dis Sci. 2003; 48:2117–2123.

7. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006; 116:254–260.

8. Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. 2006; 332:11–17.

9. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006; 101:2646–2654.

10. Johansson J, Johnsson F, Joelsson B, Florén CH, Walther B. Outcome 5 years after 360 degree fundoplication for gas-tro-oesophageal reflux disease. Br J Surg. 1993; 80:46–49.

11. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management–the Genval Workshop Report. Gut. 1999; 44(Suppl 2):S1–S16.

12. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005; 100:283–289.

13. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: fol-low-up of a randomized controlled trial. JAMA. 2001; 285:2331–2338.

14. American Gastroenterological Association. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011; 140:1084–1091.

15. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2007; 25:385–392.

16. Sinn DH, Kim JH, Kim S, et al. Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. Aliment Pharmacol Ther. 2008; 27:1275–1281.

17. DeVault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100:190–200.

18. Hirano I, Richter JE. Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007; 102:668–685.

19. Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008; 23:8–22.

20. Sung HJ, Chung WC, Roh JW, et al. Prediction of the response to proton pump inhibitor treatment using wireless ambulatory pH monitoring in patients with globus sense. Korean J Gastroenterol. 2015; 65:85–89.

TOOLS

Similar articles